Research
Hormonal
Nanomedicine delivery systems can enhance the efficacy of glucose-lowering drugs by enabling site-specific delivery to macrophages, potentially inducing plaque regression.
This is currently a research area. While standard GLP-1 injections work, scientists are developing nanoparticle versions that might target heart plaques directly. This is not yet available for routine clinical use.
ModerateConditionalMEDIUM confidence
We specifically focus on how nanomedicines can be used for the site-specific delivery of antidiabetic medicines for the treatment of diabetes-associated atherosclerosis.
Why this rating
Based on murine models and theoretical frameworks; no human clinical data for nanomedicine GLP-1 delivery cited.
Source
The role of nanosystems in the delivery of glucose-lowering drugs for the preemption and treatment of diabetes-associated atherosclerosis
Luke Conroy et al. · American Journal of Physiology-Cell Physiology · 2024
DOI 10.1152/ajpcell.00695.2023
narrative_reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →